A new randomized, placebo-controlled clinical trial has found that short-term supplementation with CBD/CBDA-rich hemp oil appears safe and well-tolerated in dogs receiving chemotherapy for lymphoma.
The study, conducted by researchers from Cornell University College of Veterinary Medicine, the University of California, and the University of Florida, was published in the Journal of Veterinary Internal Medicine. The trial enrolled 25 client-owned dogs diagnosed with high-grade lymphoma. Nineteen of the dogs completed the five-week study, during which they received either CBD/CBDA-rich hemp oil capsules or a placebo while undergoing one cycle of CHOP chemotherapy.
The primary outcomes assessed were adverse events, quality of life, and the pharmacokinetics of the chemotherapy drug doxorubicin, measured by area under the curve (AUC). Researchers found no serious adverse events in the CBD/CBDA group and no significant differences in hematologic or biochemical markers compared to placebo. While doxorubicin exposure was not initially different between groups, by week five the placebo group had a higher AUC than the CBD/CBDA group.
Mean quality of life scores did not differ significantly, with the CBD/CBDA group averaging 10.75 compared to 7.56 in the placebo group. The findings suggest that CBD/CBDA-rich hemp oil does not negatively interact with chemotherapy and is well tolerated in dogs with lymphoma, though researchers note that more studies are needed to assess long-term effects and therapeutic benefits.
